Results 111 to 120 of about 1,053,112 (188)

Overcoming Target Driven Fratricide for T Cell Therapy

Frontiers in Immunology, 2018
Chimeric Antigen Receptor (CAR) T cells expressing the fusion of the NKG2D protein with CD3ζ (NKG2D-CAR T Cells) acquire a specificity for stress-induced ligands expressed on hematological and solid cancers.
Eytan Breman, Benjamin Demoulin, Sophie Agaugué, Sebastien Mauën, Alexandre Michaux, Lorraine Springuel, Julien Houssa, Fanny Huberty, Céline Jacques-Hespel, Céline Marchand, Jérôme Marijsse, Thuy Nguyen, Nancy Ramelot, Benjamin Violle, Dorothée Daro, Peter De Waele, David E. Gilham, Valérie Steenwinckel   +17 more
doaj   +1 more source

MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer

BMC Cancer, 2014
BackgroundNKG2D (natural killer group 2, member D) is thought to play an important role in mediating the activation of anticancer immune response.
Hanbyoul Cho, J. Chung, Sunghoon Kim, T. Braunschweig, T. Kang, Jennie Kim, E. Chung, S. Hewitt, Jae-Hoon Kim   +8 more
semanticscholar   +1 more source

The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected and cancer cells.

Frontiers in Immunology, 2014
NKG2D and DNAM-1 are two activating receptors, present on the surface of NK cells and other cells of the immune system. Their ligands – MICA, MICB, ULBP1-6 for NKG2D, PVR/CD155 and Nectin-2/CD112 for DNAM-1 - can be constitutively expressed at low levels
Cristina eCerboni, Cristina eCerboni, Cinzia eFionda, Cinzia eFionda, Alessandra eSoriani, Alessandra eSoriani, Alessandra eZingoni, Alessandra eZingoni, Margherita eDoria, Marco eCippitelli, Marco eCippitelli, Angela eSantoni, Angela eSantoni, Angela eSantoni   +13 more
doaj   +1 more source

Soluble NKG2D ligands impair CD8⁺ T cell antitumor function dependent of NKG2D downregulation in neuroblastoma. [PDF]

Oncol Lett, 2023
Zhang Y, Luo F, Dong K.
europepmc   +1 more source

The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands. [PDF]

Int J Mol Sci, 2022
Maurer S, Zhong X, Prada BD, Mascarenhas J, de Andrade LF.   +4 more
europepmc   +1 more source

β-catenin attenuation leads to up-regulation of activating NKG2D ligands and tumor regression in Braf^V600E-driven thyroid cancer cells. [PDF]

Front Immunol, 2023
Zou M, Al-Yahya S, Al-Alwan M, BinEssa HA, Khabar KSA, Almohanna F, Assiri AM, Altaweel A, Qattan A, Meyer BF, Alzahrani AS, Shi Y.   +11 more
europepmc   +1 more source

Levels of Soluble NKG2D Ligands and Cancer History in Patients Starting Hemodialysis. [PDF]

Front Nephrol, 2022
Nagai K, Tawara T, Usui J, Ebihara I, Ishizu T, Kobayashi M, Maeda Y, Kobayashi H, Yamagata K.   +8 more
europepmc   +1 more source

Inhibition of miR-20a by pterostilbene facilitates prostate cancer cells killed by NK cells via up-regulation of NKG2D ligands and TGF-β1down-regulation. [PDF]

Heliyon, 2023
Youlin K, Simin L, Jian K, Li Z.
europepmc   +1 more source

Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands. [PDF]

Med Oncol, 2023
Li G, Nikkhoi SK, Hatefi A.
europepmc   +1 more source

T cells with split CARs specific for NKG2D ligands and PD-L1 exhibit improved selectivity towards monocyte-derived cells while effective in eliminating acute myeloid leukaemia in vivo. [PDF]

J Cancer Res Clin Oncol, 2023
Sun L, Jiang G, Ng YY, Xiao L, Du Z, Wang S, Zhu J.   +6 more
europepmc   +1 more source